First US biosimilar MAb on the horizon as Celltrion files Remsima
This article was originally published in SRA
Executive Summary
In a further sign that serious biosimilar competition is on the US horizon, Celltrion has filed for Food and Drug Administration's approval of Remsima, its biosimilar version of Johnson & Johnson/ Merck's Remicade (infliximab)1. Celltrion says that 'barring any setbacks', it expects approval of the drug within a year.